XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 9,277 $ 34,470 $ 43,582 $ 108,215
Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 4,278 4,822 10,798 12,167
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 3,191 5,987 14,630 14,805
APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 1,808 23,661 18,154 81,243
Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 5,395 28,042 24,807 93,376
Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 3,882 6,428 18,775 14,839
Performance Enzymes        
Disaggregation of Revenue [Line Items]        
Total revenues 8,710 31,146 37,503 100,774
Performance Enzymes | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 4,278 3,654 8,865 8,514
Performance Enzymes | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 2,624 3,831 10,484 11,017
Performance Enzymes | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 1,808 23,661 18,154 81,243
Novel Biotherapeutics        
Disaggregation of Revenue [Line Items]        
Total revenues 567 3,324 6,079 7,441
Novel Biotherapeutics | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 0 1,168 1,933 3,653
Novel Biotherapeutics | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 567 2,156 4,146 3,788
Novel Biotherapeutics | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues $ 0 $ 0 $ 0 $ 0